The effect of catheter based renal symthetic denervation on renin-angiotensin-aldosterone system in patients with resistant hypertension

Chinese Journal of Cardiology

Volumn 41, Issue 1, 2013, Pages 3-7

  Wang, Li ^a   Lu, Cheng Zhi ^b   Zhang, Xin ^b   Luo, Di ^a   Zhao, Bin ^a   Yu, Xiang ^b   Xia, Da Sheng ^b   Chen, Xin ^b   Zhao, Xiang Dong ^b  

^a TIANJIN FIRST CENTRAL HOSPITAL   (China)

^b NONE

Author keywords

Catheter ablation; Hypertension; Renin angiotensin system

Indexed keywords

ALDOSTERONE; ANGIOTENSIN II; CREATININE;

ARTICLE; BLOOD PRESSURE MEASUREMENT; CATHETERIZATION; CLINICAL ARTICLE; GLOMERULUS FILTRATION RATE; HEART RATE; HUMAN; KIDNEY DENERVATION; PLASMA RENIN ACTIVITY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RESISTANT HYPERTENSION; RETROSPECTIVE STUDY;

EID: 84875763794     PISSN: 02533758     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0253-3758.2013.01.002     Document Type: Article

References (15)

1. Perkovic V, Huxley R, Wu Y, et al. The burden of blood pressure-related disease: a neglected priority for global health. Hypertension, 2007, 50:991-997.
2. Krum H, Schlaich M, Whitbourn R, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet, 2009, 373: 1275-1281.
3. Moser M, Setaro J F. Clinical practice. Resistant or difficult-to-control hypertension. N Engl J Med, 2006, 355:385-392.
4. Calhoun D A, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation, 2008, 117:e510-e526.
5. Sarafidis P A, Bakris G L. Resistant hypertension: an overview of evaluation and treatment. J Am Coll Cardiol, 2008, 52: 1749-1757.
6. Grassi G, Cattaneo B M, Seravalle G, et al. Baroreflex control of sympathetic nerve activity in essential and secondary hypertension. Hypertension, 1998, 31:68-71.
7. Bakris G L, Hart P, Ritz E. Beta blockers in the management of chronic kidney disease. Kidney Int, 2006, 70:1905-1913.
8. Campese V M, Ye S, Zhong H. Downregulation of neuronal nitric oxide synthese and interleukin-1 beta mediates angiotensin II dependent stimulation of sympathetic nerve activity. Hypertension, 2002, 39(2 Pt 2):519-524.
9. Grimson K S. Total thoracic and partial to total lumbar sympathectomy and celiac ganglionectomy in the treatment of hypertension. Ann Surg, 1941, 114:753-775.
10. Knepper P A, Neudorff L G. Hypertension: surgical treatment by transthoracic thoracolumbar sympathectomy. Mo Med, 1949, 46: 855-860.
11. Symplicity HTN-2 Investigators, Esler M D, Krum H, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet, 2010, 376:1903-1909.
12. Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension, 2011, 57:911-917.
13. 2012, 40: 14-17.
14. Mahfoud F, Schlaich M, Kindermann I, et al. Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. Circulation, 2011, 123: 1940-1946.
15. Witkowski A, Prejbisz A, Florczak E, et al. Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea. Hypertension, 2011, 58:559-565.